3-Year Follow-up of Chemotherapy Following Radium-223 Dichloride (Ra-223) in Castration-Resistant Prostate Cancer (CRPC) Patients (Pts) With Symptomatic Bone Metastases (Mets) From ALSYMPCA

被引：0
|
作者：
Koenig, E. [1 ]
Sartor, O. [2 ]
Coleman, R. E. [3 ]
Nilsson, S. [4 ]
Voyelzang, N. [5 ]
Staudacher, K. [6 ]
Thuresson, M. [7 ]
Parker, C. [8 ,9 ]
机构：
[1] Outpatient Clin Urol, Berlin, Germany
[2] Tulane Canc Ctr, New Orleans, LA USA
[3] Univ Sheffield, Weston Pk Hosp, Sheffield, S Yorkshire, England
[4] Karolinska Univ Hosp, Stockholm, Sweden
[5] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[6] Bayer AS, Oslo, Norway
[7] Statisticon AB, Uppsala, Sweden
[8] Royal Marsden NHS Fdn Trust, Sutton, Grossbritannien, England
[9] Inst Canc Res, Sutton, Grossbritannien, England
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0099
引用
收藏
页码：86 / 86
页数：1
相关论文
共 50 条
  • [21] SAFETY OF CYTOTOXIC CHEMOTHERAPY FOLLOWING RADIUM-223 CHLORIDE (RA-223) THERAPY IN THE PHASE 3 ALSYMPCA STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES
    Sartor, O.
    Coleman, R. E.
    Nilsson, S.
    Vogelzang, N.
    Cross, A.
    O'Bryan-Tear, G.
    Staudacher, K.
    Garcia-Vargas, J. E.
    Zou, J.
    Parker, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 308 - 309
  • [22] Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA trial
    Strauss, A.
    Parker, C.
    Garcia-Vargas, J.
    O'Bryan-Tear, G.
    Fang, F.
    Vogelzang, N. J.
    ONKOLOGIE, 2013, 36 : 78 - 78
  • [23] Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases.
    Nilsson, Sten
    Sartor, A. Oliver
    Bruland, Oyvind S.
    Fang, Fang
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Radium-223 dichloride (Ra-223) improves survival in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets): nursing roles in implementing this new treatment (tx) option
    Causer, L.
    Johnson, B.
    Sicari, R.
    Lavent, F.
    Lien, L. M. E.
    Jensen, T.
    Wahba, M.
    Parker, C.
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2014, 18 : S21 - S21
  • [25] Hematologic safety of Ra-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases from the phase III ALSYMPCA trial
    Parker, Chris
    Garcia-Vargas, Jose E.
    O'Bryan-Tear, C. Gillies
    Fang, Fang
    Vogelzang, Nicholas J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group
    Wedel, S.
    Wiechno, P.
    Helle, S., I
    Logue, J.
    Nilsson, S.
    Sartor, O.
    Coleman, R. E.
    Kliment, J.
    Fang, F.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 86 - 87
  • [27] Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group
    Wiechno, P.
    Helle, S. I.
    Logue, J.
    Nilsson, S.
    Sartor, O.
    Coleman, R. E.
    Kliment, J.
    Fang, F.
    Parker, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S690 - S691
  • [28] PAIN AND QUALITY OF LIFE (QOL) ANALYSES FROM THE PHASE 3 RANDOMIZED ALSYMPCA STUDY WITH RADIUM-223 DICHLORIDE (RA-223) IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS WITH BONE METASTASES
    Tomblyn, Michael
    Nilsson, Sten
    Vogelzang, Nicholas
    Sartor, A. Oliver
    Cislo, Paul
    Van Gool, Renilt
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF UROLOGY, 2013, 189 (04): : E293 - E293
  • [29] External-beam radiation therapy (EBRT) use and safety with Radium-223 dichloride (Ra) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial
    Stroelin, P.
    O'Sullivan, J.
    Sartor, O.
    Parker, C.
    Hoskin, P.
    Widmark, A.
    Mellado, B.
    Helle, S.
    Aksnes, A.
    Garcia-Vargas, J.
    Nilsson, S.
    Oncology Research and Treatment, 2015, 38 : 82 - 82
  • [30] Hematologic safety of radium-223 dichloride (Ra-223) in the phase 3 ALSYMPCA trial in castration-resistant prostate cancer (CRPC) patients with bone metastases: Baseline prognostic factor subgroup analysis
    O'Sullivan, J.
    Johannessen, D. C.
    Widmark, A.
    Syndikus, I.
    James, N.
    Dall'Oglio, M.
    Haugen, I.
    Cross, A.
    Garcia-Vargas, J.
    Vogelzang, N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S688 - S688
12345